carnitine has been researched along with Bacterial Disease in 9 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " All of these approaches, either collectively or individually, hold considerable promise that the prevalence of adverse events associated with bacteria in platelet products will decline significantly in the very foreseeable future." | 2.42 | Improving the bacteriological safety of platelet transfusions. ( Baeza, F; Blajchman, MA; Goldman, M, 2004) |
| " The vast knowledge on the carnitine/acylcarnitine translocase is essential both as a progress in basic science and as instrument to foresee therapeutic or toxic effects of xenobiotics and drugs." | 1.42 | Mitochondrial carnitine/acylcarnitine translocase: insights in structure/ function relationships. Basis for drug therapy and side effects prediction. ( Console, L; Giangregorio, N; Indiveri, C; Tonazzi, A, 2015) |
| "In patients with bacterial infections the granulocyte carnitine concentrations (126." | 1.29 | The variation of carnitine content in human blood cells during disease--a study in bacterial infection and inflammatory bowel disease. ( Böhles, H; Demirkol, M; Sewell, AC, 1994) |
| "Carnitine metabolism was studied in 16 pediatric patients with various infections under the treatment with cefditoren pivoxil (CDTR-PI) in granular form." | 1.29 | [Effect of cefditoren pivoxil on carnitine metabolism in pediatric patients]. ( Chiba, S; Fujii, R; Meguro, H; Mori, A; Mori, T; Numazaki, K; Satoh, Y; Sunakawa, K; Terashima, I; Toyonaga, Y, 1993) |
| " This study indicated that there was a decrease in free carnitine levels in plasma, but there were no clinical symptoms or adverse effects associated with carnitine reduction in patients during the 7-day multiple administration of S-1108." | 1.29 | Carnitine status and safety after administration of S-1108, a new oral cephem, to patients. ( Fujita, Y; Hiraga, Y; Inamatsu, T; Nishikawa, T; Ohmichi, M; Saito, A; Shimada, J; Shimada, K; Shimizu, K; Tanimura, M, 1993) |
| "Carnitine has been hypothesized to be a semi-essential nutrient in the nutrition of critically ill patients." | 1.28 | Increased acylcarnitine clearance and excretion in septic rats. ( Albrecht, RM; Crady, SK; Davis, AT; Scholten, DJ; Strong, SA, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (66.67) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tonazzi, A | 1 |
| Giangregorio, N | 1 |
| Console, L | 1 |
| Indiveri, C | 1 |
| Blajchman, MA | 1 |
| Goldman, M | 1 |
| Baeza, F | 1 |
| Hayashi, M | 1 |
| Tomita, M | 1 |
| Linz, DN | 1 |
| Garcia, VF | 1 |
| Arya, G | 1 |
| Hug, G | 1 |
| Tombragel, E | 1 |
| Landrigan, E | 1 |
| Chuck, G | 1 |
| Tsoras, M | 1 |
| Ryan, M | 1 |
| Ziegler, MM | 1 |
| Demirkol, M | 1 |
| Sewell, AC | 1 |
| Böhles, H | 1 |
| Fujii, R | 1 |
| Chiba, S | 1 |
| Numazaki, K | 1 |
| Mori, T | 1 |
| Terashima, I | 1 |
| Meguro, H | 1 |
| Mori, A | 1 |
| Toyonaga, Y | 1 |
| Sunakawa, K | 1 |
| Satoh, Y | 1 |
| Shimizu, K | 1 |
| Saito, A | 1 |
| Shimada, J | 1 |
| Ohmichi, M | 1 |
| Hiraga, Y | 1 |
| Inamatsu, T | 1 |
| Shimada, K | 1 |
| Tanimura, M | 1 |
| Fujita, Y | 1 |
| Nishikawa, T | 1 |
| Davis, AT | 1 |
| Crady, SK | 1 |
| Strong, SA | 1 |
| Albrecht, RM | 1 |
| Scholten, DJ | 1 |
| Gadzhiev, AA | 1 |
| Nartsissov, RP | 1 |
| Gashimova, RA | 1 |
| Gasanov, SSh | 1 |
2 reviews available for carnitine and Bacterial Disease
| Article | Year |
|---|---|
Improving the bacteriological safety of platelet transfusions.
Topics: Automation; Bacterial Infections; Blood Component Removal; Blood Platelets; Blood Preservation; Carn | 2004 |
Mechanistic analysis for drug permeation through intestinal membrane.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bacterial Infections; Caco-2 Cells | 2007 |
7 other studies available for carnitine and Bacterial Disease
| Article | Year |
|---|---|
Mitochondrial carnitine/acylcarnitine translocase: insights in structure/ function relationships. Basis for drug therapy and side effects prediction.
Topics: Amino Acid Sequence; Animals; Anti-Bacterial Agents; Bacterial Infections; Brain Diseases; Cardiovas | 2015 |
Weanling and adult rats differ in fatty acid and carnitine metabolism during sepsis.
Topics: 3-Hydroxybutyric Acid; Aging; Animals; Bacterial Infections; Blood Glucose; Carnitine; Fatty Acids; | 1995 |
The variation of carnitine content in human blood cells during disease--a study in bacterial infection and inflammatory bowel disease.
Topics: Acute Disease; Adolescent; Adult; Bacterial Infections; Carnitine; Child; Chronic Disease; Crohn Dis | 1994 |
[Effect of cefditoren pivoxil on carnitine metabolism in pediatric patients].
Topics: Bacterial Infections; Carnitine; Cephalosporins; Child; Child, Preschool; Female; Humans; Infant; Ma | 1993 |
Carnitine status and safety after administration of S-1108, a new oral cephem, to patients.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bacterial Infections; Carnitine; Cephalosporin | 1993 |
Increased acylcarnitine clearance and excretion in septic rats.
Topics: Animals; Bacterial Infections; Carnitine; Disease Models, Animal; Kidney; Liver; Male; Muscles; Myoc | 1991 |
[Correction of metabolic changes in neutrophils with carnitine chloride in newborn infants at risk of developing bacterial infections].
Topics: Administration, Oral; Bacterial Infections; Carnitine; Female; Humans; Infant, Newborn; Male; Neutro | 1990 |